OncoMed Pharmaceuticals, Inc.(OMED: Quote), Thursday said it initiated Phase 1b/2 clinical trial of its anti-cancer stem cell product candidate, demcizumab or OMP-21M18 in ovarian cancer. Demcizumab will be tested in combination with paclitaxel in patients with platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer, in the study. Progression-free survival and response rate mark the primary endpoints of the Phase 2 part of the trial.
The company said that this trial is its fourth Phase 1b trial of demcizumab, and the second portion of this protocol would represent the first Phase 2 trial of demcizumab. OncoMed also said that Phase 1b trials in pancreatic cancer and non-small cell lung cancer are currently enrolling patients.
"We have observed strong preclinical efficacy of demcizumab and paclitaxel in patient-derived ovarian cancer xenograft models, as well as early evidence of activity of demcizumab in ovarian cancer in the Phase 1a single-agent study of demcizumab." said Jakob Dupont, Chief Medical Officer of OncoMed.
Click here to receive FREE breaking news email alerts for OncoMed Pharmaceuticals Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org